Olumide B. Gbolahan, MBBS, MSc

• A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  • Phase

    I
  • Conditions

    Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
  • Location

    Winship Cancer Institute

• Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

  • Phase

    II
  • Conditions

    Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  • Phase

    I
  • Conditions

    Advanced Solid Tumors, Colorectal Cancer
  • Location

    Winship Cancer Institute

• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  • Phase

    III
  • Conditions

    Biliary Tract Cancer
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

  • Phase

    III
  • Conditions

    Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
  • Location

    Emory Saint Joseph's Hospital, Winship Cancer Institute

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  • Phase

    III
  • Conditions

    Colorectal Neoplasms
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

  • Phase

    I/II
  • Conditions

    Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
  • Location

    Winship Cancer Institute

• 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

  • Phase

    II
  • Conditions

    Malignant Digestive System Neoplasm
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

  • Phase

    III
  • Conditions

    Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Emory Johns Creek Hospital, Winship Cancer Institute

• Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

  • Phase

    II
  • Conditions

    Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

  • Phase

    I
  • Conditions

    IDH1-Mutated Malignancies
  • Location

    Winship Cancer Institute

A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling

Cancer Letters

Comprehensive Characterization of the Immune Microenvironment of Colorectal and Gastric Signet Ring Cell Cancer

Cells

Sexual Health in Cancer Care—A Gap in Understanding

JAMA Internal Medicine

A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations

The Oncologist

First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors

Cancer Research Communications

Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101

Future Oncology

Feasibility and Safety of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Neuroendocrine Tumor in a Patient With Sickle Cell Anemia

Clinical Nuclear Medicine

A pilot study of the immune microenvironment of GI neuroendocrine carcinoma

Endocrine Related Cancer

Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer

JAMA Network Open

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma

Current Oncology

Role of chemoradiation in gallbladder cancer—a single institution retrospective analysis

Journal of Gastrointestinal Oncology

Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control

Journal of Cancer Research and Clinical Oncology

Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018

Cancer Control

Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer?

Journal of Surgical Research

Patient‐reported geriatric assessment‐based frailty index among older adults with gastrointestinal malignancies

Journal of the American Geriatrics Society

Differences in Pretreatment Frailty Across Gastrointestinal Cancers in Older Adults: Results From the Cancer and Aging Resilience Evaluation Registry

JCO Oncology Practice

Geriatric Assessment Predictors of 1-Year Mortality in Older Adults With GI Malignancies: A Survival Tree Analysis

JCO Clinical Cancer Informatics

Time to treatment initiation and its impact on real‐world survival in metastatic colorectal cancer and pancreatic cancer

Cancer Medicine

Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?

The American Journal of Surgery

Re: Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Journal of the National Cancer Institute

03/09/2026

Good

02/13/2026

If someone is referring him for his expertise then his experience is valid but as a surgeon I didn't get what I expected or scheduled.

12/20/2025

Amazing doctor with good bedside manner taking into account quality of life which is very important to me!

11/17/2025

Dr Gbolahan very caring and answers all my questions

10/11/2025

Good job

08/20/2025

Dr. Gbaldahan was very kind, attentive and courteous. He answered questions and extended conversations to understand my concerns. He was professional and talked to show understanding and concern.

08/16/2025

Dr. Gbolohan was extraordinarily informative, courteous, and sensitive to my situation.

07/19/2025

This is the most professional, courteous, knowledgeable group of people I have ever worked with. Dr. Gbolohan was top-notch. I would highly recommend him to anybody.

05/03/2025

Fantastic conversation very detailed.

04/26/2025

Great

03/10/2025

Dr. Gbolahan is kind, patient, honest, thoughtful, and thorough.

01/05/2025

Muy bueno

01/04/2025

Dr. Gbolohan was kind, concerned and forthright. It was a pleasure meeting him.

11/03/2024

Dr. Gbolahan is amazing. He listens and is great in sharing information. He is always concerned about me as the pt and my wife who is the primary care taker.

11/02/2024

I loved Dr. Gbolihan!!

09/26/2024

Dr Gbolahan was very caring, knowledgeable, & informative. He clarified everything & gave me options. He mentioned I'd be cared for by another doctor when I return for a follow up. I wish him well.

09/25/2024

Dr. Olu patiently answered all my questions and gave me his perspective on my current condition.

08/15/2024

Good

08/09/2024

Dr Gbolahan did a fantastic job

05/25/2024

Dr. B is awesome explain everything in detail, listen to you, and take the necessary time with you.

05/23/2024

If they are diagnosed with cancer this is the only hospital that I would ever refer them toI.

05/06/2024

Dr. Gbolahan and his entire team are the BEST! He takes time to address all of our concerns. He reviewed my father's charts in detail before he met with us and heard our concerns. Because my father's situation is complex/multiple issues, he and his team looked at his situation from all angles and based his treatment and care from that. Different from past experiences where we felt like a part of a standard assembly line. He takes extra measure to go above and beyond. Because he looked at the WHOLE picture, and not through a single oncologist lens, my father is feeling better than he has in 6 mos. We Thank you!

05/03/2024

Fantastic job